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Under the proposed DPDA, care providers (the nephrology community) are not incentivized or empowered to optimize the road to transplantation for their patients and there is a covert financial disincentive to provide transplantation as a treatment. The success of this five-year demonstration project would primarily be assessed by improvements in dialysis care processes and related cost savings. The inclusion of a few minimal standards for transplantation, is unlikely to mitigate the strong financial incentive to maintain patients on dialysis. It is foreseeable the patients enrolled and maintained in the DPDA will be phenotypically at "low risk" for high health care utilization,(7, 8) and will contribute significantly to the denominator of the cost per member ratio that drives provider profit in the model proposed by the DPDA. Since pre-ESRD and post-transplant patients are excluded, there is no accountability or potential for cost savings for improving the care of these patients A truly integrated CKD care model should be centered around the patient and not organized by treatment modality (i.e. pre-end stage, dialysis, transplantation).(9) Providers would be contracted to manage all aspects of CKD in the entire population. Accordingly, providers would focus on treatments that provided the most value (best outcomes for least cost) including preventing CKD (e.g. by screening high risk groups), slowing progression of disease (e.g. through multi-disciplinary CKD clinics), and maximizing the use of transplantation among patients who progress to ESRD (e.g. by investing in living and deceased organ donation, re-designing post-transplant care models, and funding the cost of
immunosuppressant drugs to improve long-term transplant survival and decrease the need for repeat transplantation).
Our assessment of the value of transplant care must evolve to include the broader perspective of patients on dialysis, and the long-term outcomes of transplant recipients (including those who return to dialysis after transplant failure), and we must advocate for systematic changes that will improve the outcomes of these patients who are currently out of sight and out of mind. Expanding our reach to these patients is unrealistic without the partnership of the general nephrology community and dialysis providers. Sadly, the DPDA was conceived without any input from the transplant community. This is deflating as Dr.
Becker has lamented past events in which the needs of transplant patients were pitted against those of dialysis patients leading to failure of legislative efforts to secure lifelong coverage of immunosuppressant drugs for kidney transplant recipients.(10) Given the reality of finite resources, dialysis providers must consider the impact of their proposals in the context of the overall value to the system. While we may differ in opinion with Becker and Nissensen as to the whether the DPDA will exacerbate disparities in access to transplantation, it is apparent that bill will not increase transplantation. We are confident that the inclusion of the transplant community in future efforts to improve the care of CKD patients would avoid similar policy blind-spots.
The formidable task of redesigning the organization of CKD care does not preclude the transplant community from moving forward with strategies to improve access to transplantation. These include removal of financial disincentives to living kidney donation, investment in novel strategies to enable patients to identify a living donor, increasing the utilization of high donor profile index kidneys and kidneys at increased risk for infectious disease transmission as defined by the Public Health Service, revision of regulatory and
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In summary, by focusing solely on dialysis the DPDA is too narrow in scope to have significant impact on the value of CKD care, will exacerbate disparities in access to transplantation and has the potential to decrease the use of transplantation as a treatment for patients with ESRD. The development of the DPDA without input from the transplant community is symptomatic of a larger problem with the modality-based organization of CKD care in which the interests of stakeholders are not aligned to improve the value of patient care across the entire spectrum of CKD. The inclusion of minimal requirements for transplant and improved transplant education in the DPDA are woefully inadequate measures. System redesign focused on investment in therapies that provide the most value including disease prevention, and transplantation is necessary but will be slow to achieve and will require the collaboration and leadership of all stakeholders. In the meantime, the transplant community should move forward with tangible solutions to improve patient access to transplantation.
